New drug cocktail targets Hard-to-Treat cancers
NCT ID NCT05910827
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new antibody called HMBD-001 combined with two existing cancer drugs (cetuximab and docetaxel) in people with advanced squamous cell cancers of the lung, head and neck, esophagus, cervix, or skin. The goal is to see if the combination is safe and can shrink tumors or delay cancer growth. About 398 participants will take part across multiple sites.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HMBD-001 (an antibody targeting HER3) combined with cetuximab and docetaxel
What this could lead to
If successful, this could offer a new treatment option for people with advanced squamous cell cancers who have run out of standard therapies.
What could go wrong
This is an early-phase trial (phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. Side effects from the drug combination are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHA Bundang Medical Center, CHA University
RECRUITINGSeongnam-si, South Korea
Contact
Contact
-
Cabrini Health
WITHDRAWNMalvern, Victoria, 3144, Australia
-
Chungbuk National University Hospital
RECRUITINGCheongju-si, South Korea
Contact
Contact
-
GenesisCare North Shore
WITHDRAWNSydney, New South Wales, 2065, Australia
-
Greenslopes Private Hospital
RECRUITINGGreenslopes, Queensland, 4120, Australia
Contact
Contact
-
ICON Cancer Centre South Brisbane
WITHDRAWNBrisbane, Queensland, 4101, Australia
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
RECRUITINGKaohsiung City, Taiwan
Contact
Contact
-
Korea University Anam Hospital
RECRUITINGSeoul, South Korea
Contact
Contact
-
Linear Clinical Research
RECRUITINGPerth, Western Australia, 6009, Australia
Contact
Contact
-
National Cancer Centre Singapore
RECRUITINGSingapore, Singapore
Contact
Contact
-
National Cheng Kung University Hospital
RECRUITINGTainan, Taiwan
Contact
Contact
-
Peninsula & South Eastern Haematology and Oncology Group
RECRUITINGFrankston, Victoria, Australia
Contact
Contact
-
Severance Hospital
RECRUITINGSeoul, South Korea
Contact
Contact
-
Southern Oncology Clinical Research Unit
RECRUITINGAdelaide, South Australia, 5042, Australia
Contact
Contact
-
Taipei Medical University - Shuang Ho Hospital
RECRUITINGTaipei, Taiwan
Contact
Contact
-
Taipei Veterans General Hospital
RECRUITINGTaipei, Taiwan
Contact
Contact
-
Tan Tock Seng Hospital
RECRUITINGSingapore, Singapore
Contact
Contact
-
The Catholic University of Korea St. Vincent's Hospital
RECRUITINGSuwon, South Korea
Contact
Contact
-
The Institute of Oncology, ARENSIA Exploratory Medicine Phase I Unit
RECRUITINGChisinau, Moldova
Contact
Contact
-
Westmead Hospital
RECRUITINGWestmead, New South Wales, 2145, Australia
Contact
Contact